iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics.
- DOI
- 10.1016/s1470-2045(17)30074-8
- Published
- 2017 Mar
- Container
- The Lancet. Oncology
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1016/s1470-2045-17-30074-8,
title = {iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics.},
author = {Seymour L and Bogaerts J and Perrone A and Ford R and Schwartz LH and Mandrekar S and Lin NU and Litière S and Dancey J and Chen A and Hodi FS and Therasse P and Hoekstra OS and Shankar LK and Wolchok JD and Ballinger M and Caramella C and de Vries EGE and RECIST working group},
year = {2017},
journal = {The Lancet. Oncology},
doi = {10.1016/s1470-2045(17)30074-8},
url = {https://doi.org/10.1016/s1470-2045(17)30074-8}
}RIS
TY - JOUR TI - iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. AU - Seymour L AU - Bogaerts J AU - Perrone A AU - Ford R AU - Schwartz LH AU - Mandrekar S AU - Lin NU AU - Litière S AU - Dancey J AU - Chen A AU - Hodi FS AU - Therasse P AU - Hoekstra OS AU - Shankar LK AU - Wolchok JD AU - Ballinger M AU - Caramella C AU - de Vries EGE AU - RECIST working group PY - 2017 JO - The Lancet. Oncology DO - 10.1016/s1470-2045(17)30074-8 UR - https://doi.org/10.1016/s1470-2045(17)30074-8 ER -
APA
L, S., J, B., A, P., R, F., LH, S., S, M., NU, L., S, L., J, D., A, C., FS, H., P, T., OS, H., LK, S., JD, W., M, B., C, C., EGE, D. V., & group, R. W. (2017). iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics.. The Lancet. Oncology. https://doi.org/10.1016/s1470-2045(17)30074-8
Source records
- pubmed · retrieved 2026-09-27T13:21:26.696Z